Equities analysts expect Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report $1.36 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Karyopharm Therapeutics’ earnings, with the highest sales estimate coming in at $4.30 million and the lowest estimate coming in at $500,000.00. Karyopharm Therapeutics posted sales of $240,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 466.7%. The business is scheduled to report its next quarterly earnings results on Thursday, November 14th.
According to Zacks, analysts expect that Karyopharm Therapeutics will report full-year sales of $12.94 million for the current year, with estimates ranging from $1.50 million to $19.20 million. For the next year, analysts forecast that the business will post sales of $59.09 million, with estimates ranging from $20.40 million to $117.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.97) by $0.26. Karyopharm Therapeutics had a negative net margin of 2,138.80% and a negative return on equity of 154.75%. The firm had revenue of $9.49 million for the quarter.
Shares of NASDAQ KPTI traded down $0.59 during trading on Wednesday, hitting $10.73. 3,715,791 shares of the company traded hands, compared to its average volume of 1,503,416. The business’s fifty day moving average is $9.29 and its 200 day moving average is $6.73. Karyopharm Therapeutics has a fifty-two week low of $3.92 and a fifty-two week high of $19.19. The firm has a market capitalization of $725.09 million, a price-to-earnings ratio of -3.42 and a beta of 2.41. The company has a debt-to-equity ratio of 1.46, a quick ratio of 6.93 and a current ratio of 6.93.
In related news, CEO Michael Kauffman sold 10,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.00, for a total value of $120,000.00. Following the sale, the chief executive officer now owns 539,767 shares in the company, valued at approximately $6,477,204. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sharon Shacham sold 20,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $12.00, for a total transaction of $240,000.00. Corporate insiders own 13.26% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can acquired a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth about $29,000. BNP Paribas Arbitrage SA increased its stake in Karyopharm Therapeutics by 169,300.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,164 shares of the company’s stock valued at $59,000 after buying an additional 10,158 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in Karyopharm Therapeutics by 12.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 11,980 shares of the company’s stock valued at $72,000 after buying an additional 1,319 shares during the last quarter. Parametric Portfolio Associates LLC purchased a new stake in Karyopharm Therapeutics in the 2nd quarter valued at about $128,000. Finally, Premier Asset Management LLC purchased a new stake in Karyopharm Therapeutics in the 2nd quarter valued at about $160,000. Institutional investors own 82.55% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for
the treatment of cancer and other major diseases. Karyopharm’s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).
See Also: Growth Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.